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Abstract Device life of the Provox Vega Indwelling
voice prosthesis is as yet untested outside Europe. The
current study examined device life and reasons for
replacement within an Australian clinical setting. Twenty-
three participants were monitored for device life and rea-
sons for replacement. Main outcome measure was days to
failure of initial device. Average device life and reasons for
replacement were secondary measures. Initial device life
data revealed 67 % had functioning devices at 3 months,
52 % at 6 months and 29 % at 12 months. Average device
life was 207 days (median of 222). The majority of devices
(97 %) failed due to leakage through the prosthesis. The
Provox Vega Indwelling voice prosthesis had favourable
device life in this cohort of patients and in comparison to
European data. Reasons for replacement were consistent
with international literature.
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Introduction
As in most international health services, tracheoesophageal
(TE) speech is the most common method of voice reha-
bilitation in Australian clinical settings [1]. Advantages of
TE speech over other available methods of alaryngeal
speech include a more natural sounding voice, superior
voice quality, improved success rates, and more immediate
voice rehabilitation [1–6]. One of the few limitations of TE
speech is the need for ongoing replacement of the voice
prosthesis by either the clinician (for indwelling devices) or
the patient (for non-indwelling devices). The most common
reason for replacement of an indwelling device is leakage
through the device. Other reasons for device removal
include leakage around the device, or fistula-related prob-
lems including granulation tissue formation or infection
[6–12].
Studies to date have revealed that, on average, the
device life of an indwelling voice prosthesis falls some-
where between 4 and 6 months for the majority of patients
[6, 9–16]. However, significant variation in device life has
been reported within patients, between different patient
groups, and across device types and geographical regions
studied [17, 18]. Studies of the Provox 1 (22.5Fr)
Indwelling voice prosthesis reported average device life
between 102 and 311 days [10, 13–15, 19]. The Provox 2
(22.5Fr) Indwelling voice prosthesis has been reported as
having an average device life between 111 and 163 days
[6, 9, 12, 16]. Similar ranges have been observed across
studies of the Blom–Singer Classic (20Fr) Indwelling voice
prosthesis, with average device life ranging from 105 to
185 days [8, 11, 14].
Reasons proposed for the diversity in device life dura-
tion observed between studies include patient characteris-
tics (e.g. dietary patterns, use of antifungal treatment,
cleaning, controlled supraesophageal reflux), treatment
characteristics (e.g. prior radiotherapy, follow-up support),
as well as socioeconomic and reimbursement factors
[11–13, 17, 20–23]. Another potential factor is device
design. As reduced device life has negative personal and
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economic implications for both patient and the health
service, developers have introduced a number of special-
ized indwelling voice prostheses. Research has shown
modifications to the standard indwelling voice prosthesis
design has significantly extended device life when com-
pared to similar devices [24, 25].
Recently a new standard silicon indwelling device, the
Provox Vega Indwelling voice prosthesis was introduced to
the market. The only report of device life of the Provox
Vega found comparable device life to the Provox 2 [17]. As
both the Provox 2 and Provox Vega are constructed from
silicone rubber, the results supported deterioration of the
new device was comparable to other silicone devices
within the same clinical setting. A second European study
conducted by Lorenz and Maier [18] reported a much
lower median device life for the Provox Vega. However,
the authors cautioned that the median device life of 88 days
(calculated from 31 devices) observed in their investigation
may have been influenced by selection bias within the
study sample and insufficient study duration [18]. This
study included 19 participants who presented to the clinic
with difficulties during a 9-month period. The authors
stated that a randomized trial of 1.5–2 years duration
would be more suitable to study device life to allow longer
observation of device life and overall representation of
both frequent and less frequent patients.
Device life is known to vary across geographical loca-
tions explained by a number of multifactoral reasons
including diet, and clinical reimbursement situations [19,
20, 26]. It is therefore important to understand the expected
device life of any new type of voice prosthesis within the
geographical context in which it is to be used. This infor-
mation can be used to inform patient choice and clinical
service management. The current prospective clinical trial
was designed to investigate the long-term performance of
the Provox Vega Indwelling voice prosthesis in laryngec-
tomized patients in Australia. As no prior device life
studies have been published pertaining to the Australian
context, a null hypothesis was assumed; that the new




This prospective study was approved by the Human
Research Ethics Committee of the Princess Alexandra
Hospital, Queensland, Australia. It was completed under a
Clinical Trial Notification (CTN) scheme and as such
complied with the strict regulatory processes, including
independent data analysis by both the research group and
the study sponsors (Atos Medical). All participants pro-
vided informed consent prior to participation.
Participants and procedures
This study arose from a larger randomized controlled
cross-over design clinical trial that explored patient’s per-
ceptions of two indwelling voice prosthesis systems: the
Provox Vega Indwelling voice prosthesis (Atos Medical)
and the Blom–Singer Classic Indwelling voice prosthesis
(Inhealth) as reported elsewhere [27, 28]. These partici-
pants were recruited from the speech pathology outpatient
files of the Princess Alexandra Hospital, Queensland,
Australia. The inclusion criteria of that study required all
participants to be TE speakers who were more than
3 months post-surgery, who had no current tracheoesoph-
ageal puncture (TEP) problems (such as enlarged TEP or
infection around the TEP) or known recurrent disease at
time of recruitment.
In the original study [27, 28] participants trialed both
devices for a 3-week period with the order of device trial
randomly allocated. The short-term component was inten-
ded to gain patient perceptions of voice effort and quality,
insertion and care of devices as well as perceptual judg-
ment of voice quality by both participants and listeners. At
the termination of the above study, individuals were pro-
vided with the prosthesis of their choice. Twenty-three
participants elected to continue with the Provox Vega
Indwelling voice prosthesis and where possible a maximum
of two devices were followed in a prospective manner until
device failure. Of this current cohort of 23, two participants
failed to complete the initial device trial; one deceased
during the trial due to reasons unrelated to the current study
or its design and one withdrew following diagnosis of
further disease leaving data for 21 participants to initial
device failure. Seventeen participants elected to trial a
second device (Fig. 1). Four elected not to continue with
the major reason being early failure of the device. For two
individuals, a trial device was removed prior to device
failure due to the presence of an infection in one patient
and a request for early device change due to upcoming
travel for the second. The data from these devices was
censored. These individuals were provided a third device
which was followed to true device failure and used in the
study analysis as their second device.
Demographics of this study include 21 participants (17
males, 4 females, mean age = 60.19 years with age range
34–72 years). Thirteen participants had undergone a stan-
dard total laryngectomy and eight a pharyngolaryngectomy
with free jejunal graft interposition. The average duration
post-surgery was 4.12 years (SD = 2.5, range 0.63–10.43
years). The majority were long-term TE speech users
with a mean duration using TE speech of 4.04 years
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(SD = 2.49, range 0.62–10.43 years). Just over half 12/21
(57 %) used 20Fr devices, while 9/21 (43 %) used 17Fr
devices. The majority 18/21 (86 %) used some form of
routine antifungal medication and 14/21 (67 %) reported
routine use of anti-reflux medication.
At the commencement of the study, participants were
instructed on cleaning and care requirements and equip-
ment to use as per the instructions for use. Antifungal and
anti-reflux medications were continued if participants were
using these prior to the study. Routine clinical reviews
occurred face to face or via telephone at regular intervals
post-insertion of a device until device failure. Duration to
device failure was recorded in days and the reasons for
replacement documented. All participants with a func-
tioning device were reviewed face to face at 12 months
post-insertion following recommendations of the study
device manual. The manual advised that laboratory testing
of simulated usage (in the absence of bacteria and yeasts)
had been performed for a period of 12 months, and as the
device had not been tested beyond 12 months, usage
beyond this point was at the sole discretion of the pre-
scriber. Considering this information, all participants with
a functioning device as reviewed by the treating clinician at
12 months (n = 6) were given the option to have the
device changed. Of these, 2 participants requested a change
of their initial device. The remaining participants elected
not to change their device and to continue until actual
device failure. For all 7 devices (across 6 participants),
duration of device life data only until 365 days is used in
the analysis. The actual device life duration ([365 days) of
the subset of 4 individuals (across 5 devices) who contin-
ued beyond 12 months is discussed separately within the
results section below.
Statistical analyses
Kaplan–Meier survival curves were created for the patients’
initial (n = 21) and second (n = 17) Provox Vega. For this
analysis, devices replaced routinely at 1 year and devices
lasting beyond 1 year were all truncated at 365 days. A log-
rank test (Mantel–Cox) was used to compare the device life
time of the initial and the second Provox Vega. Reasons for
replacement were detailed descriptively. For all analyses,
significance was set at p \ 0.05.
Results
Early leakage before 2 months (60 days) was seen in 19 %
(4/21) of the initial Provox Vega devices. The proportion of
patients with a functioning device at 4, 6, 8 and 12 months
was 67, 52, 43 and 29 %, respectively.
Figure 2 shows the plot of the survival times separated
for a patients’ initial (n = 21) and second (n = 17) Provox
Participants followed to failure 
of first device (n = 21)
Withdrew early (n = 2)
(1 x deceased & 1 x lung mets)
No. of eligible participants 
meeting inclusion criteria from 
prior study (n = 23)
Discontinued following failure of first device (n =  4 ) 
(3 x early failure, 1 x unwilling to continue travelling 
distance for study) 
Participants followed to failure of 
















Analysis of initial device  (n=21)
Analysis of total device life (n=38)
Analysis of reasons for replacement within one year (n=31)
Fig. 1 Details and justification
for patient numbers and attrition
throughout study
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Vega device. For this analysis, device life which extended
beyond 1 year was truncated to 365 days as some devices
were changed as part of routine care (as requested by
participant) at 1 year. No censored devices are included in
this plot. The average device life of the initial placed Vega
was 208 days (SD ± 126.9, min–max: 23–365) with a
median of 251 days. The device life of the second placed
Vega was 205 days (SD ± 110.6, min–max 19–365) with
a median of 220 days. A log-rank test comparing the sur-
vival plots for both devices revealed no significant differ-
ence (v2 = 0.133, p = 0.716) in average device life
between the patients initial and second Provox Vega. The
average for the total 38 Provox Vega Indwelling devices
was 207 days (SD ± 118) with a median of 222 days.
Average device life was examined between the 14 par-
ticipants on anti-reflux medication and the 7 who were not.
Calculated using the average device life per individual, and
using only device life durations up to a maximum of
365 days, the average device life of the 14 participants on
anti-reflux medication was 193 days (SD = 117) and the
group not on medication was 206 days (SD = 120). There
was no significant (t = -0.252, p = 0.804) difference
between the groups.
For the 4 participants (2 on anti-reflux medication, 2 not)
who continued with their initial or second device beyond
12 months, 3 had one device last longer than 1 year (398,
693, 486 days) and 1 had 2 devices last longer than 1 year
(initial device = 383 days, second device = 445 days).
Thirty-one devices were replaced within 1 year (Table 1).
The majority of those devices 30/31 (97 %) failed due to
leakage through the prosthesis and the one remaining device
(3 %) failed due to patient report of slight changes in voice
effort and voice quality. Nil incidents of leakage around the
voice prosthesis were observed in this cohort. Five devices
remained in situ for longer than 1 year. Three of these were
removed for device failure, two, because of leakage through
the voice prostheses at 398 and 383 days, and one for noted
changes in voice effort at 486 days. The remaining 2/5
devices were replaced at 445 and 693 days for management
of granulation formation and long time device in situ,
respectively.
Discussion
For the initial Provox Vega device trial (n = 21), early
failure was observed in only a small proportion of the
group (19 %.). This is consistent with previous literature
which has reported up to 20 % can experience early leak-
age within the first month [8, 16]. Examination of pre trial
data revealed a history of early failure with other devices
for these participants. At 6 months more than half the
group (52 %) continued with their initial device, while at
12 months, 29 % continued with their original device.
Laccourreye et al. [10] reported from a cohort of 100
devices that 65.9 and 23.7 % were in situ at 6 and
12 months post-insertion, respectively. These results sug-
gest for this cohort the Provox Vega is a suitable voice
prosthesis with favourable device life in those that do not
have a current history of early device failure.
The reasons for device failure and change in this study
were primarily leakage through the device (97 %), con-
sistent with previous literature [7, 9, 17, 19]. There were no
incidences of leakage around or other significant compli-
cations as the reason for replacement. This may be related
to the fact that the trial excluded patients with current TEP
problems. One finding of note was the instance for one
participant where device failure was identified by noted
changes to voice quality and an obvious increase in
speaking effort both within and outside the 12-month
timeframe (278 and 486 days). Clinical examination con-
firmed no leakage, and eliminated TEP causes for voice
changes and together with improved voice on replacement
suggest a change to the opening/closing functionality of the
valve mechanism within the prosthesis.
The average device duration for the 38 devices of 207
days (median 222) was found to exceed other studies on
device life for the Provox Vega (i.e. median device life of
74–93 days). In comparison average device life was almost
3 months longer for this cohort. Hence the null hypothesis
set for this study is rejected. Comparison against other
standard silicon indwelling devices illustrated device life is
comparable to studies of the Provox 1 device [14, 15] and
exceeds those for the Provox 2 or Blom–Singer Classic
Indwelling Voice Prostheses [6, 9, 12, 16]. To date there
have been no other studies of indwelling device life within
Fig. 2 Kaplan–Meier survival curves of the patients’ initial (n = 21)
and second (n = 17) Provox Vega
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the Australian context. It is unclear whether longer device
life is a potential characteristic of this geographical region
or the device itself. Possible factors which may account for
this increase in device life could relate to increased patient
monitoring during the study period and patterns of cleaning
and care. The rigorous requirements of this clinical trial
ensured patients were followed regularly and monitored
between insertion and replacement of the device. Certainly
some studies have identified a positive influence on device
life with increased patient follow-up [22]. Participants were
instructed to care and clean their Provox Vega voice
prosthesis as per the instructions for use. The provision of
appropriate cleaning equipment (brushes and flushes) and
compliance with recommendations were regularly dis-
cussed at face to face or phone review sessions. Prior to the
study, flushes were not used in the cleaning routines of any
patients and cleaning and care was not regularly discussed
in sessions beyond the initial training and skills develop-
ment sessions or as clinically warranted. Involvement in
the larger clinical trial (from which the current cohort was
recruited) identified a patient preference for the cleaning
equipment of the Provox Vega (brush and flush) when
compared to a comparator device in a short-term trial [28].
Hence the current participants may have had greater
compliance to cleaning routines than prior to the trial. Free
et al. [20] explored the relationship of regular airflow
provided via the Provox Flush cleaning device on biofilm
development and found the flush had a cleansing effect,
reducing biofilm formation which could potentially assist
with device life. It is possible that using both a brush and a
flush and improved patient compliance with cleaning may
have influenced device life in the current cohort. This issue
warrants further investigation.
Boscolo-Rizzo et al. [11] suggested a possible associa-
tion between uncontrolled reflux and limited device life,
with the mean device life of patients with reflux being just
over half of those without. Lorenz et al. also demonstrated
that the lifespan of the voice prosthesis is reduced in those
with reflux symptoms [18]. Considering that over half of
the current patient cohort who reported experiencing reflux
were taking regular anti-reflux medications to control their
symptoms, it is possible this may be a favourable influ-
encing factor on device life. Whilst in our study the device
life of participants who were receiving and not receiving
anti-reflux medication was not found to be significantly
different, the potential impact of uncontrolled reflux on
device life remains a possible factor which should be
considered for patients experiencing limited device life. In
addition to reflux medication, the majority of participants
(18/21, 86 %) from this cohort were also regular users of
antifungal medications prior to this study, and continued
their usual practice during the Provox Vega trial. This may
have had an impact on extended device life and warrants
further investigation.
One final factor relates to individual patient behaviour,
and their tolerance of periods of minor leakage prior to
requesting device change. Within Australia and other
international settings there are issues relating to purchasing
and provision of equipment and its reimbursement. Clini-
cians and patients are acutely aware of the costs associated
with short device life where funding restrictions apply for
voice prostheses. Furthermore, within Australia the geo-
graphical expanse of the country and distances necessary to
travel for device replacement may foster increased patient
tolerance of mild intermittent leakage prior to prosthesis
replacement. Cornu et al. [13] described this behaviour/
phenomenon as patients taking ‘‘a more conservative
approach’’ and proposed that it may have contributed to the
extended device life in their cohort in South Africa. While
the potential for this phenomenon to have influenced
device life in the current study cannot be fully discounted,
the increased monitoring of patients in the study largely
prevented this from occurring and replacements were
identified promptly and device changes actioned in a timely
manner. In future studies, informing patients to contact the
study team at the point of initial identification of any
leakage would help ensure this possible source of data bias
was controlled for.
Examination of the individual device durations high-
lighted considerable variability both within individuals and
between participants in the current group. Within this
clinical setting, the authors have observed variation in
device life of individual patients as a regular occurrence,
regardless of types of devices (indwelling or non-indwell-
ing or different manufacturers). Other researchers have also
noted high intra-individual differences in device life [18].
There does not appear to be one clear reason to explain this
variability. It is more likely the result of a multitude of
Table 1 Summary Information regarding sizes and reasons for





replacement (n = 31)
First Vega
(n = 17)
20 Fr: 11 4 mm: 1 Leakage through:
16 (52 %)
17 Fr: 6 6 mm: 1
8 mm: 7 Increased speaking




20 Fr: 8 6 mm: 2 Leakage through:
14 (45 %)
17 Fr: 6 8 mm: 3
10 mm: 7
12.5 mm: 2
a 17Fr 8 mm Provox Vega
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factors that may not be controlled for (e.g. fluctuations in
patient health; dietary changes; climate changes, etc.).
Acknowledging this degree of inherent variability in device
life of indwelling prostheses exists it may be optimal to
trial at least two devices prior to determining suitability of
a device and potential device life for any individual.
Conclusion
Results demonstrate that for this clinical cohort, the Provox
Vega Indwelling voice prosthesis was a favourable device
in the Australian context with an average device life of
207 days (median 222). Reasons for device life failure
were consistent with prior literature. In Australia equip-
ment provision for this clinical population is subject to
financial pressures and as a consequence device life is an
important factor when selecting an appropriate indwelling
device for both patients and clinicians. Further exploration
of the possible relationship between cleaning practices,
equipment and device life is warranted.
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